The heavy reliance on ChT-based cohorts also limits generalizability to patients treated with newer regimens such as HER2-targeted agents, CDK4/6 inhibitors, or immune checkpoint inhibitors, which are increasingly standard in contemporary BC care. The gene discussed is ERBB2; the disease is breast cancer.